Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.36 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8077519 | 1.00 | TSHR (0.48) | TSHRMAPTABCC4ALDH1A1LMNA | |
| SCHEMBL8072036 | 1.00 | TSHR (0.48) | TSHRMAPTABCC4ALDH1A1LMNA | |
| SCHEMBL8005897 | 1.00 | TSHR (0.48) | TSHRMAPTABCC4ALDH1A1LMNA | |
| SCHEMBL1607801 | 0.98 | TSHR (0.44) | TSHRMAPTABCC4ALDH1A1LMNA | |
| SCHEMBL1118529 | 0.98 | TSHR (0.44) | TSHRMAPTABCC4ALDH1A1LMNA | |
| SCHEMBL7819862 | 0.90 | — | — | |
| SCHEMBL19644547 | 0.80 | TSHR (0.46) | TSHRMAPTABCC4ALDH1A1LMNA | |
| SCHEMBL20972793 | 0.80 | TSHR (0.46) | TSHRMAPTABCC4ALDH1A1LMNA | |
| SCHEMBL6601699 | 0.79 | — | — | |
| SCHEMBL9185106 | 0.79 | ALDH1A1 (0.50) | TSHRALDH1A1LMNATP53USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110082312-A1 | PRODUCTION OF COMPOUNDS COMPRISING CF30 GROUPS | MERCK PATENT GESELLSCHAFT MIT DESCHRANKTER HAFTUNG (DE) | 2011-04-07 | — | — | US | disclosed |
| EP-2280918-A1 | PRODUCTION OF COMPOUNDS COMPRISING CF3O GROUPS | Merck Patent GmbH (DE) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009141053-A1 | PRODUCTION OF COMPOUNDS COMPRISING CF3O GROUPS | MERCK PATENT GMBH, (DE) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082312-A1 | PRODUCTION OF COMPOUNDS COMPRISING CF30 GROUPS | ZRANB2, ORC3, IKZF2 | TSHR 2163/4885MAPT 4545/4885ABCC4 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.